Annals of Surgical Oncology

, Volume 14, Issue 2, pp 885–892 | Cite as

Opa Interacting Protein 5 (OIP5) Is a Novel Cancer-testis Specific Gene in Gastric Cancer

  • Yoshito Nakamura
  • Fumiaki Tanaka
  • Hisashi Nagahara
  • Keisuke Ieta
  • Naotsugu Haraguchi
  • Koshi Mimori
  • Atsushi Sasaki
  • Hiroshi Inoue
  • Katsuhiko Yanaga
  • Masaki Mori



Identification of novel cancer-specific antigens is important for the advancement of immunotherapy. Our aim was to identify cancer-specific genes in gastric cancer.


Using cDNA microarray analysis, we detected genes overexpressed specifically in gastric cancer cells. The expression levels of selected genes, including OIP5, was confirmed by real time RT-PCR analysis in tumor/normal paired bulk samples of 58 clinical cases. The expression levels of selected genes in normal tissues were also determined with a human total RNA master panel. We also compared the expression status of OIP5 with that of the other known cancer-testis specific genes.


Twenty-two genes were determined to be upregulated in gastric cancer cells. Among these, three genes (CDC6, Exo1, and OIP5) were selected and confirmed to be upregulated in the tumor tissue compared to normal tissue. A human total RNA master panel demonstrated that OIP5, but not Exo1 or CDC6, showed high specificity in testis. Thus OIP5 may be considered a cancer-testis specific gene. In 58 clinical cases of gastric cancer examined, we found OIP5 gene expression in 27 cases (47%). Thirteen of these 27 cases showed no expression of the known cancer specific genes such as MAGE-1, MAGE-3 or NY-ESO-1.


Using a combination of LMD and microarray, we identified OIP5 as a cancer-testis specific gene. Further expression analysis in a set of clinical cases revealed that OIP5 may be a novel immunotherapy target for patients with gastric cancer.


OIP5 PRAME Gastric cancer Laser micro dissection Cancer testis antigen 



Opa interacting protein 5


cancer testis antigen


glyceraldehyde 3-phosphate dehydrogenase


laser microdissection


reverse transcriptase-polymerase chain reaction



We thank Ms. T. Shimooka, Ms. K. Ogata, Ms. M. Oda, Ms. N. Kasagi, and Ms. Y. Nakagawa for their excellent technical assistance.


  1. 1.
    Jemal A, Tiwari RC, Murray T, et al. Cancer statistics. CA Cancer J Clin 2004; 54:8–29PubMedCrossRefGoogle Scholar
  2. 2.
    Sadanaga N, Nagashima H, Mashino K, et al. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 2001; 7:2277–84PubMedGoogle Scholar
  3. 3.
    Gilboa E, Nair SK, Lyerly HK. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother 1998; 46:82–7PubMedCrossRefGoogle Scholar
  4. 4.
    Shimizu K, Thomas EK, Giedlin M, Mule JJ. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. Cancer Res 2001; 61:2618–24PubMedGoogle Scholar
  5. 5.
    van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254:1643–7PubMedCrossRefGoogle Scholar
  6. 6.
    Inoue H, Mori M, Honda M, et al. The expression of tumor-rejection antigen ‘MAGE’ genas in human gastric carcinoma. Gastroenterology 1995; 109:1522–5PubMedCrossRefGoogle Scholar
  7. 7.
    Inoue K, Ozeki Y, Suganuma T, Sugiura Y, Tanaka S. Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression. Cancer 1997; 79:206–13PubMedCrossRefGoogle Scholar
  8. 8.
    Tanaka F, Fujie T, Tahara K, et al. Induction of antitumor CTLs with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24. Cancer Res 1997; 57:4465–8PubMedGoogle Scholar
  9. 9.
    Fujie T, Tahara K, Tanaka F, Mori M, Takesako K, Akiyoshi T. A MAGE-1-encoded HLA-A24-binding synthetic peptide induces specific anti-tumor cytotoxic T lymphocytes. Int J Cancer 1999; 80:169–72PubMedCrossRefGoogle Scholar
  10. 10.
    Wang Y, Wu XJ, Zhao AL, Yuan YH, Chen YT, Jungbluth AA, et al. Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer. Cancer Immunol 2004; 4:11Google Scholar
  11. 11.
    Laura J. van ‘t Veer, Hongyue Dai, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415:530–6Google Scholar
  12. 12.
    Quackenbush J. Microarray data normalization and transformation. Nat Genet 2002;32:496–501PubMedCrossRefGoogle Scholar
  13. 13.
    Mori M, Mimori K, Inoue H, Barnard GF, Tsuji K, Nanbara S. Detection of cancer micrometastases in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res 1995; 55:3417–20PubMedGoogle Scholar
  14. 14.
    Ogawa K, Utsunomiya T, Mimori K, et al. Clinical significance of human kallikrein gene 6 messenger RNA expression in colorectal cancer. Clin Cancer Res 2005; 11:2889–93PubMedCrossRefGoogle Scholar
  15. 15.
    Mashino K, Sadanaga N, Tanaka F, et al. Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br J Cancer 2001; 85:713–20PubMedCrossRefGoogle Scholar
  16. 16.
    Jungblunth AA, Stockert E, Chen YT, et al. Monoclonal antibody MA454 reveals a heteroeneous expression pattern of MAGE-1 antigen in formalin-mixed paraffin embedded lung tumours. Br J Cancer 2000; 83:493–7CrossRefGoogle Scholar
  17. 17.
    Sadanaga N, Nagashima H, Tahara K, Yoshikawa Y, Mori M. The heterogeneous expression of MAGE-3 protein: difference between primary lesions and metastatic lymph nodes in gastric carcionoma. Oncol Rep 1999; 6:975–7PubMedGoogle Scholar
  18. 18.
    Cross SS, Hamdy FC, Deloulme JC, Rehman I. Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers. Histopathology 2005; 46:256–69PubMedCrossRefGoogle Scholar
  19. 19.
    Ji H, Liu YE, Jia T, et al. Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing. Cancer Res 1997; 57:759-–64PubMedGoogle Scholar
  20. 20.
    Bruening W, Giasson BI, Klein-Szanto AJ, Lee VM, Trojanowski JQ, Godwin AK. Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary. Cancer 2000; 88:2154–63PubMedCrossRefGoogle Scholar
  21. 21.
    El-Rifai W, Moskaluk CA, Abdrabbo MK, Harper J, Yoshida C, Riggins GJ, Frierson Jr HF, Powell SM. Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res 2002; 62:6823–6PubMedGoogle Scholar
  22. 22.
    Yanagawa N, Tamura G, Honda T, Endoh M, Nishizuka S, Motoyama T. Demethylation of the synuclein gene CpG Island in primary gastric cancers and gastric cancer cell lines. Clin Cancer Res 2004; 10:2447–51PubMedCrossRefGoogle Scholar
  23. 23.
    Heizmann CW, Fritz G, Schafer BW. S100 proteins: structure, functions and pathology. Front Biosci 2002; 7:1356–68CrossRefGoogle Scholar
  24. 24.
    Jia T, Liu YE, Liu J, Shi YE. Stimulation of breast cancer invasion and metastasis by synuclein . Cancer Res 1999; 59:742–7PubMedGoogle Scholar
  25. 25.
    Pawlak A, Toussaint C, Levy I, Bulle F, Poyard M, Barouki R, Guellaen G. Characterization of a large population of mRNAs from human testis. Genomics 1995; 27:151–8CrossRefGoogle Scholar
  26. 26.
    Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, de Smet C, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997; 27:199–208CrossRefGoogle Scholar
  27. 27.
    Boon K, Edwards JB, Siu IM, et al. Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes. Oncogene 2003; 22:7687–94PubMedCrossRefGoogle Scholar
  28. 28.
    Oberthuer A, Hero B, Spitz R, Berthold F, Fischer M. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin Cancer Res 2004; 10:4307–13PubMedCrossRefGoogle Scholar
  29. 29.
    van Baren N, Chambost H, Ferrant A, et al. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br J Haematol 1998; 102:1376–9PubMedCrossRefGoogle Scholar
  30. 30.
    Epping MT, Wang L, Edel MJ, Carlee L, Hernandez M, Bernards R. The human tumor antigen prame is a dominant repressor of retinoic acid receptor signaling. Cell 2005; 122:835–47PubMedCrossRefGoogle Scholar
  31. 31.
    Steinbach D, Hermann J, Viehmann S, Zintl F, Gruhn B. Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. Cancer Genet Cytogenet 2002; 133:118–23PubMedCrossRefGoogle Scholar
  32. 32.
    Steinbach D, Viehmann S, Zintl F, Gruhn B. PRAME gene expression in childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet 2002; 138:89–91PubMedCrossRefGoogle Scholar
  33. 33.
    Tajeddine N, Gala JL, Louis M, Van Schoor M, Tombal B, Gailly P. Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspase-independent cell death in vitro and reduces tumorigenicity in vivo. Cancer Res 2005; 65:7348–55PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2006

Authors and Affiliations

  • Yoshito Nakamura
    • 1
    • 2
    • 3
  • Fumiaki Tanaka
    • 1
    • 2
  • Hisashi Nagahara
    • 1
    • 2
  • Keisuke Ieta
    • 1
    • 2
  • Naotsugu Haraguchi
    • 1
    • 2
  • Koshi Mimori
    • 1
    • 2
  • Atsushi Sasaki
    • 1
    • 2
  • Hiroshi Inoue
    • 1
    • 2
  • Katsuhiko Yanaga
    • 3
  • Masaki Mori
    • 1
    • 2
  1. 1.Department of Surgery and Molecular Oncology, Medical Institute of BioregulationKyushu UniversityBeppuJapan
  2. 2.Core Research for Evolutional Science and Technology (CREST)Japan Science and Technology Agency (JST)SaitamaJapan
  3. 3.Department of SurgeryJikei University School of MedicineTokyoJapan

Personalised recommendations